{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:58:12Z","timestamp":1793332692136,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Radius Health, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00223-018-0450-0","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T13:59:25Z","timestamp":1530107965000},"page":"540-545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide"],"prefix":"10.1007","volume":"103","author":[{"given":"Jean-Yves","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Michael","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"issue":"1","key":"450_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157(1):141\u2013149","journal-title":"Endocrinology"},{"issue":"4","key":"450_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-015-0050-1","volume":"98","author":"P Esbrit","year":"2016","unstructured":"Esbrit P, Herrera S, Portal-N\u00fa\u00f1ez S, Nogu\u00e9s X, D\u00edez-P\u00e9rez A (2016) Parathyroid hormone-related protein analogs as osteoporosis therapies. Calcif Tissue Int 98(4):359\u2013369","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"450_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G (2016) Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99(5):489\u2013499","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"450_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100(2):697\u2013706","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"450_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"issue":"1","key":"450_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32(1):24\u201333","journal-title":"J Bone Miner Res"},{"key":"450_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","volume":"95","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G (2017) One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone 95:143\u2013150","journal-title":"Bone"},{"key":"450_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","volume":"97","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone 97:314\u2013319","journal-title":"Bone"},{"issue":"26","key":"450_CR9","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318(26):1728\u20131733","journal-title":"N Engl J Med"},{"issue":"8","key":"450_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, for the FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"9041","key":"450_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535\u20131541","journal-title":"Lancet"},{"issue":"24","key":"450_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, for the Fracture Intervention Trial Research Group (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082","journal-title":"JAMA"},{"issue":"4","key":"450_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570\u2013578","journal-title":"Endocr Rev"},{"issue":"1","key":"450_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM (2017) Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32(1):17\u201323","journal-title":"J Bone Miner Res"},{"issue":"2","key":"450_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00223-017-0266-3","volume":"101","author":"E Gielen","year":"2017","unstructured":"Gielen E, Bergmann P, Bruy\u00e8re O, Cavalier E, Delanaye P, Goemaere S, Kaufman JM, Locquet M, Reginster JY, Rozenberg S, Vandenbroucke AM, Body JJ (2017) Osteoporosis in frail patients: a consensus paper of the Belgian Bone Club. Calcif Tissue Int 101(2):111\u2013131","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"450_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-014-9844-9","volume":"94","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Rizzoli R, Cooper C, Reginster JY (2014) Challenges for the development of bone-forming agents in Europe. Calcif Tissue Int 94(5):469\u2013473","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"450_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00223-016-0127-5","volume":"98","author":"SH Ralston","year":"2016","unstructured":"Ralston SH, Rizzoli R (2016) New targets and new treatments: recent advances in the treatment of musculoskeletal disease. Calcif Tissue Int 98(4):317\u2013318","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"450_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 92(2):200\u2013210","journal-title":"Mayo Clin Proc"},{"key":"450_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00163","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab.\u00a0\n                    https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"450_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jbmr.3163","volume":"32","author":"EV McCloskey","year":"2017","unstructured":"McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA (2017) The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res 32(8):1625\u20131631","journal-title":"J Bone Miner Res"},{"issue":"19","key":"450_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"4","key":"450_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jocd.2013.09.018","volume":"17","author":"EM Lewiecki","year":"2014","unstructured":"Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL (2014) Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom 17(4):490\u2013495","journal-title":"J Clin Densitom"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0450-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T23:19:47Z","timestamp":1561591187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0450-0","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jean-Yves Reginster reports consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Pierre Fabre, and Radius Health, Inc.; lecture fees when speaking at the invitation of the following sponsors: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council (DRC); and grant support from industry (all through his institution) from: IBSA-Genevrier, Mylan, CNIEL, and Radius Health, Inc. Gary Hattersley, Gregory C. Williams, Ming-yi Hu, and Lorraine A. Fitzpatrick are employees of Radius Health, Inc. and own stock in Radius Health, Inc. E. Michael Lewiecki has received institutional grant\/research support from Amgen, PFEnex, and Mereo; has served on scientific advisory boards for Amgen, Radius Health, Inc., Shire, Alexion, Ultragenyx, and Sandoz; and serves on the speakers\u2019 bureau for Shire, Alexion, and Radius Health, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Participants in the phase 3 ACTIVE study provided written informed consent, and the protocol was approved by the respective institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and Informed Consent"}}]}}